Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methysergide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methysergide SCHEMBL29359107 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL467884 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL41843 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL7088235 | 0.99 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL28086572 | 0.99 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methsergide SCHEMBL29601488 | 0.95 | KMT2A (0.91) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL41844 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL21803661 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL29408580 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL28196309 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4584243-B1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4584243-A1 | CROSSLINKERS | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025056814-A1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| EP-4524128-A1 | BENZOPHENONE CROSSLINKERS | Hemoteq AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-11 | — | — | US | disclosed |
| EP-2046410-B1 | MANUFACTURE, METHOD, AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | HEMOTEQ AG (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-2386322-B1 | Production, method and use of medical products which release agents for opening blood vessels on a permanent basis | HEMOTEQ AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20120316496-A1 | USE OF COMPOSITIONS TO COAT CATHETER BALLOONS AND COATED CATHETER BALLOONS | HEMOTEQ AG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2491962-A1 | Medical product for treating closures of bodily passages and preventing reclosures | Hemoteq AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110287169-A1 | MEDICAL PRODUCT FOR TREATING STENOSIS OF BODY PASSAGES AND FOR PREVENTING THREATENING RESTENOSIS | HEMOTEQ AG | 2011-11-24 | — | — | US | disclosed |
| EP-2386322-A2 | Production, method and use of medical products which release agents for opening blood vessels on a permanent basis | Hemoteq AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254838-A1 | METHOD FOR TRANSMITTING DATA ON STEREOSCOPIC IMAGE, METHOD FOR PLAYING BACK STEREOSCOPIC IMAGE, AND METHOD FOR CREATING FILE OF STEREOSCOPIC IMAGE | ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) | 2011-10-20 | — | — | US | disclosed |
| US-20110160698-A1 | Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis | HEMOTEQ AG (DE) | 2011-06-30 | — | — | US | disclosed |
| EP-2269664-A2 | Medical product for treating closures of bodily passages and preventing reclosures | Hemoteq AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-20100179475-A1 | MEDICAL PRODUCT FOR TREATING STENOSIS OF BODY PASSAGES AND FOR PREVENTING THREATENING RESTENOSIS | HEMOTEQ AG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100063585-A1 | MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | HEMOTEQ AG (DE) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063585-A1 | MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | RICTOR, VEGFA, RPTOR | HTR1A 883/4885HTR2C 2570/4885HTR2B 1112/4885 |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | HTR1F, HTR1D, HTR1E | HTR1A 4/4885HTR2C 17/4885HTR2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.